These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8874973)

  • 21. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs.
    Traub WH; Leonhard B
    Chemotherapy; 1997; 43(1):10-20. PubMed ID: 8996736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of the susceptibility of Staphylococcus sp. and Enterococcus sp. to teicoplanin and vancomycin].
    Mimica I; Mendes CM; Mimica L; Oplustil C; Pignatari AC; Sader H
    Rev Assoc Med Bras (1992); 1996; 42(3):147-50. PubMed ID: 9138356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
    O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.
    Andrew JH; Wale MC; Wale LJ; Greenwood D
    J Antimicrob Chemother; 1987 Aug; 20(2):213-21. PubMed ID: 2822649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optochin revisited: defining the optimal type of blood agar for presumptive identification of Streptococcus pneumoniae.
    Gardam MA; Miller MA
    J Clin Microbiol; 1998 Mar; 36(3):833-4. PubMed ID: 9508326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of different Mueller-Hinton agars and media age on Etest susceptibility testing of tigecycline.
    Tan TY; Ng LS; Chen DM
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):93-5. PubMed ID: 20727479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
    Nonhoff C; Denis O; Struelens MJ
    Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
    Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro susceptibilities of clinical isolates of coagulase-negative staphylococci to glycopeptide antibiotics].
    Kato D; Hanaki H; Cui L; Oguri T; Hiramatsu K
    Jpn J Antibiot; 1998 Dec; 51(12):735-45. PubMed ID: 10077772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
    Thamlikitkul V
    J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Teicoplanin and vancomycin susceptibility in Staphylococcus aureus and coagulase-negative staphylococci].
    Caiaffa Filho HH; Lima Mde P; Sinto SI; Andriolo A; Mendes CM
    Rev Assoc Med Bras (1992); 1994; 40(2):77-80. PubMed ID: 7820154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin tolerance in enterococci.
    Saribas S; Bagdatli Y
    Chemotherapy; 2004 Nov; 50(5):250-4. PubMed ID: 15528891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
    Wootton M; MacGowan AP; Walsh TR; Howe RA
    J Clin Microbiol; 2007 Feb; 45(2):329-32. PubMed ID: 17108069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhibition of hemolytic activity of Staphylococcus aureus 3-hemolysin by an exosubstance produced by some Enterococcus faecalis strains].
    Vítkova A; Votava M
    Epidemiol Mikrobiol Imunol; 2005 Feb; 54(1):11-5. PubMed ID: 15807382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of imipenem in Mueller-Hinton agar stored at 4 degrees C.
    Turgeon PL; Desrochers C
    Antimicrob Agents Chemother; 1985 Nov; 28(5):711-2. PubMed ID: 3867331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A suitable blood agar containing human blood especially for the use in laboratories of developing countries.
    Niederstebruch N; Sixt D; Benda BI; Banboye N
    J Infect Dev Ctries; 2017 Jun; 11(5):399-406. PubMed ID: 30943176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard Nutrient Agar 1 as a substitute for blood-supplemented Müller-Hinton agar for antibiograms in developing countries.
    Niederstebruch N; Sixt D
    Eur J Clin Microbiol Infect Dis; 2013 Feb; 32(2):237-41. PubMed ID: 22926453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.